Showing 461-470 of 9112 results for "".
Golden Achievement: Dr. Michael Gold on Lifetime Award at CSF 2016
https://practicaldermatology.com/topics/practice-management/golden-achievement-dr-michael-gold-on-lifetime-award-at-csf-2016/18712/Michael H. Gold, MD was recognized December 2016 at the Cosmetic Surgery Forum in Las Vegas with the Lifetime Contribution to Aesthetics Award by CSF Founder Joel Schlessinger, MD. Speaking about the award, Dr. Gold shares his perspective as a global educator and practitioner (Dr. Gold cofounded theSunscreen Advancements: What to Know
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sunscreen-advancements-what-to-know/23698/New sunscreen formulations are enhancing protection for more patients.Currents: Calming the Inflammation of Acne and Rosacea
https://practicaldermatology.com/topics/acne-rosacea/currents-calming-the-inflammation-of-acne-and-rosacea/23729/At-home Medical Aesthetic Devices: What Your Patients Should Be Aware Of
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/at-home-medical-aesthetic-devices-what-your-patients-should-be-aware-of/23149/Despite some reputable standouts, most consumer-grade medical aesthetic devices are manufactured overseas and sold online and tend to be of somewhat suspect quality.Asset Protection: A Matter Of Degree
https://practicaldermatology.com/topics/practice-management/asset-protection-a-matter-of-degree/21431/How to protect your personal and professional assets.BrightGuard Covers NYC, Galderma Uncovers Rosacea Burden, Dermira's Qbrexza Approved
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-brightguard-covers-nyc-galderma-uncovers-rosacea-burden-dermira-s-qbrexza-approved/18288/BrightGuard dispensers have now been installed at 53 public pools and 11 beaches in various locations throughout metropolitan New York. The impact of rosacea can be significant for affected patients. According to survey results released last month by Galderma, 86% of patients with rosacea modify theAllergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National PsoriasisHumira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaAAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing
https://practicaldermatology.com/topics/skin-cancer-photoprotection/-dermwiretv-aad-week-of-science-adcetris-ctcl-data-siliq-pricing/18482/It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JAEncouraging Conversation
https://practicaldermatology.com/topics/skin-cancer-photoprotection/encouraging-conversation-40-gep-testing-for-adjuvant-radiation-therapy-candidates/37104/Two studies validate the 40-GEP test for identifying patients most likely to benefit from adjuvant radiation therapy